002252 上海莱士
已收盘 10-30 15:00:00
资讯
新帖
简况
上海莱士2026年三季报:血液制品夯实底盘,创新药研产能力持续完善
中国财富通 · 10-28
上海莱士2026年三季报:血液制品夯实底盘,创新药研产能力持续完善
血制品行业承压后,上海莱士加码押注创新药
华尔街见闻 · 10-27
血制品行业承压后,上海莱士加码押注创新药
上海莱士最新公告:前三季度净利润同比下降33.44%
证券之星 · 10-27
上海莱士最新公告:前三季度净利润同比下降33.44%
股市必读:上海莱士新发布《关于第二期员工持股计划非交易过户完成的公告》
证券之星 · 10-26
股市必读:上海莱士新发布《关于第二期员工持股计划非交易过户完成的公告》
上海莱士(002252)披露第二期员工持股计划非交易过户完成公告,10月23日股价下跌0.21%
证券之星 · 10-23
上海莱士(002252)披露第二期员工持股计划非交易过户完成公告,10月23日股价下跌0.21%
上海莱士:2026年新一轮回购自2026年9月24日起实施
证券之星 · 10-21
上海莱士:2026年新一轮回购自2026年9月24日起实施
股市必读:上海莱士新发布《云南信托-上海莱士第二期员工持股集合资金信托计划信托合同》
证券之星 · 10-20
股市必读:上海莱士新发布《云南信托-上海莱士第二期员工持股集合资金信托计划信托合同》
股市必读:上海莱士新发布《关于第六届董事会第二十三次(临时)会议决议公告》
证券之星 · 10-14
股市必读:上海莱士新发布《关于第六届董事会第二十三次(临时)会议决议公告》
上海莱士(002252)披露第二期员工持股计划调整事项,10月13日股价下跌1.2%
证券之星 · 10-13
上海莱士(002252)披露第二期员工持股计划调整事项,10月13日股价下跌1.2%
上海莱士(002252)10月8日主力资金净卖出6243.45万元
证券之星 · 10-09
上海莱士(002252)10月8日主力资金净卖出6243.45万元
上海莱士(002252)9月30日主力资金净卖出2047.54万元
证券之星 · 10-08
上海莱士(002252)9月30日主力资金净卖出2047.54万元
股市必读:上海莱士新发布《关于第二期员工持股计划实施进展的公告》
证券之星 · 10-08
股市必读:上海莱士新发布《关于第二期员工持股计划实施进展的公告》
上海莱士收购BI生产基地:工厂易手,行业换挡
同花顺 · 09-29
上海莱士收购BI生产基地:工厂易手,行业换挡
上海莱士回应收购CDMO工厂:意欲补齐创新药产业化能力
格隆汇 · 09-29
上海莱士回应收购CDMO工厂:意欲补齐创新药产业化能力
上海莱士(002252)9月28日主力资金净买入1209.55万元
证券之星 · 09-29
上海莱士(002252)9月28日主力资金净买入1209.55万元
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
证券之星 · 09-28
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
上海莱士:9月24日公司首次回购股份10880400股
证券日报 · 09-27
上海莱士:9月24日公司首次回购股份10880400股
全球首创APC机制挺进III期 上海莱士SR604商业化前景如何?
新浪证券 · 09-24
全球首创APC机制挺进III期 上海莱士SR604商业化前景如何?
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
证券之星 · 09-24
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权
智通财经 · 09-23
上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权
加载更多
公司概况
公司名称:
上海莱士血液制品股份有限公司
所属行业:
医药制造业
上市日期:
2008-06-23
主营业务:
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。
发行价格:
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":4.73,"timestamp":1793343789000,"preClose":4.7,"halted":0,"volume":38730648,"delay":0,"changeRate":0.0064,"floatShares":6588000000,"shares":6593000000,"eps":0.1647,"marketStatus":"已收盘","change":0.03,"latestTime":"10-30 15:00:00","open":4.68,"high":4.77,"low":4.66,"amount":183000000,"amplitude":0.0234,"askPrice":4.74,"askSize":2030,"bidPrice":4.73,"bidSize":148,"shortable":0,"etf":0,"ttmEps":0.1647,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":4.7,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":5.17,"lowLimit":4.23,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":0.95,"roa":"--","peRate":28.718883,"roe":"3.01%","epsLYR":0.24,"committee":-0.460849,"marketValue":31183000000,"turnoverRate":0.0059,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-02。","floatMarketCap":31162000000},"requestUrl":"/m/hq/s/002252/","defaultTab":"news","newsList":[{"id":"2678456504","title":"上海莱士2026年三季报:血液制品夯实底盘,创新药研产能力持续完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2678456504","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678456504?lang=zh_cn&edition=full","pubTime":"2026-10-28 15:56","pubTimestamp":1793174219,"startTime":"0","endTime":"0","summary":"上海莱士血液制品股份有限公司于10月27日晚披露第三季度业绩报告。报告期内,上海莱士持续推进“拓浆+脱浆”战略:血液制品业务加强浆源保障与市场拓展,创新药管线推进多适应症临床开发,同时通过拟收购张江生物药生产基地,提前布局后续制造能力。管线梯次推进,研发成果加速成型上海莱士持续保持研发投入。从前三季度的经营安排看,上海莱士正在深化血液制品业务的同时,将创新药布局从临床研发延伸至产业化准备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=YJ73Yjc3hGY%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1161","IBBQ","BK0196","MEDX","BK0188","159992","LNGR","BK0046","BK0239","BK0028","002252","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678109380","title":"血制品行业承压后,上海莱士加码押注创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2678109380","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678109380?lang=zh_cn&edition=full","pubTime":"2026-10-27 23:07","pubTimestamp":1793113666,"startTime":"0","endTime":"0","summary":"10月27日晚,上海莱士披露2026年三季报。第三季度实现营业收入17.35亿元,同比下降18.9%...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3784595","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","002252","BK0196","06978","BK1161","159992","LNGR","IBBQ","BK0028","MEDX","BK1574","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678174108","title":"上海莱士最新公告:前三季度净利润同比下降33.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678174108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678174108?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:51","pubTimestamp":1793101870,"startTime":"0","endTime":"0","summary":"上海莱士(002252.SZ)公告称,第三季度营业收入为17.35亿元,同比下降18.90%;归属于上市公司股东的净利润为3.18亿元,同比下降27.93%。前三季度营业收入为49.44亿元,同比下降18.83%;归属于上市公司股东的净利润为9.79亿元,同比下降33.44%。注:公司Q3净利润3.18亿,Q2净利润3.45亿,据此计算,Q3净利润环比下降8%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700037943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678135410","title":"股市必读:上海莱士新发布《关于第二期员工持股计划非交易过户完成的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678135410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678135410?lang=zh_cn&edition=full","pubTime":"2026-10-26 00:58","pubTimestamp":1792947490,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,上海莱士报收于4.77元,下跌0.21%,换手率0.84%,成交量55.62万手,成交额2.67亿元。公司公告汇总:上海莱士完成第二期员工持股计划非交易过户,涉及股份2,219.90万股,占总股本0.34%,过户价格2.82元/股。持股计划存续期不超过60个月,锁定期不低于12个月,分三期解锁,解锁比例分别为40%、30%、30%。本计划与控股股东、实际控制人及其他持股计划不构成一致行动关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002252","BK0188","BK0239","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677397360","title":"上海莱士(002252)披露第二期员工持股计划非交易过户完成公告,10月23日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677397360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677397360?lang=zh_cn&edition=full","pubTime":"2026-10-23 22:38","pubTimestamp":1792766293,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,上海莱士报收于4.77元,较前一交易日下跌0.21%,最新总市值为314.47亿元。近日,上海莱士发布《关于第二期员工持股计划非交易过户完成的公告》。公告显示,公司已完成第二期员工持股计划的非交易过户,将2,219.90万股公司股份从回购专用账户过户至员工持股计划专用账户,占公司总股本的0.34%,过户价格为2.82元/股。持股计划存续期不超过60个月,锁定期不低于12个月,分三期解锁,解锁比例分别为40%、30%、30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300045730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0196","BK0028","BK0239","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677724671","title":"上海莱士:2026年新一轮回购自2026年9月24日起实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2677724671","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677724671?lang=zh_cn&edition=full","pubTime":"2026-10-21 20:52","pubTimestamp":1792587143,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士10月20日在投资者关系平台上答复投资者关心的问题。回购注销能够减少总股本、提升每股收益,以实际行动维护公司价值,增强广大投资者信心。公司2026年新一轮回购自2026年9月24日起实施,截至2026年9月30日,已通过股份回购专用证券账户以集中竞价方式累计回购公司股份17,003,200股,成交金额85,685,929.10元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100039208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0028","BK0188","BK0046","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676386496","title":"股市必读:上海莱士新发布《云南信托-上海莱士第二期员工持股集合资金信托计划信托合同》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676386496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676386496?lang=zh_cn&edition=full","pubTime":"2026-10-20 01:39","pubTimestamp":1792431548,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘,上海莱士报收于4.89元,上涨0.62%,换手率0.48%,成交量31.55万手,成交额1.54亿元。股本股东变化股东户数变动截至2026年10月9日公司股东户数为11.9万户,较9月10日增加2717.0户,增幅为2.34%;户均持股数量由5.67万股减少至5.54万股,户均持股市值为28.04万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000001889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0196","002252","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675699143","title":"股市必读:上海莱士新发布《关于第六届董事会第二十三次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675699143","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675699143?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:38","pubTimestamp":1791913089,"startTime":"0","endTime":"0","summary":"公司公告汇总关于第六届董事会第二十三次(临时)会议决议公告上海莱士第六届董事会第二十三次(临时)会议于2026年10月10日以通讯方式召开,审议通过《关于修订公司〈第二期员工持股计划〉及其摘要的议案》和《关于修订公司〈第二期员工持股计划管理办法〉的议案》。关于修订公司第二期员工持股计划相关事项的公告2026年10月10日董事会审议通过第二期员工持股计划相关事项修订。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0046","BK0188","BK0239","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675733701","title":"上海莱士(002252)披露第二期员工持股计划调整事项,10月13日股价下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675733701","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675733701?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:33","pubTimestamp":1791884006,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘,上海莱士报收于4.95元,较前一交易日下跌1.2%,最新总市值为326.34亿元。该股当日开盘4.97元,最高4.99元,最低4.92元,成交额达2.87亿元,换手率为0.88%。近日,上海莱士披露关于修订公司第二期员工持股计划相关事项的公告。因公司实施2025年度权益分派、回购股份注销及部分高管离职,对员工持股计划的购买价格、参与对象、股票规模、资金来源及管理模式进行调整。本次修订在董事会权限范围内,无需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300029302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0239","BK0046","BK0188","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674215881","title":"上海莱士(002252)10月8日主力资金净卖出6243.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674215881","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674215881?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:17","pubTimestamp":1791508637,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月8日收盘,上海莱士报收于5.06元,下跌4.89%,换手率1.95%,成交量128.59万手,成交额6.63亿元。10月8日的资金流向数据方面,主力资金净流出6243.45万元,占总成交额9.42%,游资资金净流入3485.96万元,占总成交额5.26%,散户资金净流入2757.49万元,占总成交额4.16%。近5日资金流向一览见下表:上海莱士融资融券信息显示,融资方面,当日融资买入8638.73万元,融资偿还4287.34万元,融资净买入4351.38万元。上海莱士主营业务:生产和销售血液制品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900007300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0196","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049709","title":"上海莱士(002252)9月30日主力资金净卖出2047.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673049709?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:07","pubTimestamp":1791421640,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月30日收盘,上海莱士报收于5.32元,上涨2.9%,换手率1.36%,成交量89.9万手,成交额4.76亿元。9月30日的资金流向数据方面,主力资金净流出2047.54万元,占总成交额4.3%,游资资金净流出336.13万元,占总成交额0.71%,散户资金净流入2383.67万元,占总成交额5.01%。近5日资金流向一览见下表:上海莱士融资融券信息显示,融资方面,当日融资买入4625.14万元,融资偿还5341.1万元,融资净偿还715.96万元。上海莱士主营业务:生产和销售血液制品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0188","BK0196","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673145090","title":"股市必读:上海莱士新发布《关于第二期员工持股计划实施进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673145090","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673145090?lang=zh_cn&edition=full","pubTime":"2026-10-08 00:59","pubTimestamp":1791392347,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,上海莱士报收于5.32元,上涨2.9%,换手率1.36%,成交量89.9万手,成交额4.76亿元。当日关注点交易信息汇总:9月30日主力资金净流出2047.54万元,占总成交额4.3%。公司公告汇总:第二期员工持股计划证券账户已于2026年9月28日开立,截至9月30日尚未持有公司股票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0188","002252","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671299291","title":"上海莱士收购BI生产基地:工厂易手,行业换挡","url":"https://stock-news.laohu8.com/highlight/detail?id=2671299291","media":"同花顺","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671299291?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:45","pubTimestamp":1790667900,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛近日,上海莱士宣布收购勃林格殷格翰(BI)中国生物药业100%股权,拿下其位于上海张江、具备6000升商业化产能的CDMO基地。这宗交易在生物医药圈引发的讨论热度,远超 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260929/c680359069.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260929/c680359069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0188","BK0046","BK0196","002252","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671821295","title":"上海莱士回应收购CDMO工厂:意欲补齐创新药产业化能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2671821295","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671821295?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:01","pubTimestamp":1790661712,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0239","BK0188","159992","002252","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671016269","title":"上海莱士(002252)9月28日主力资金净买入1209.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671016269","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671016269?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:07","pubTimestamp":1790644055,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月28日收盘,上海莱士报收于5.08元,上涨1.2%,换手率0.98%,成交量64.38万手,成交额3.26亿元。近5日资金流向一览见下表:上海莱士融资融券信息显示,融资方面,当日融资买入2847.78万元,融资偿还4811.08万元,融资净偿还1963.3万元。上海莱士主营业务:生产和销售血液制品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900008250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0196","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409363","title":"股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409363","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409363?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:15","pubTimestamp":1790529311,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,上海莱士报收于5.02元,上涨1.01%,换手率1.23%,成交量80.95万手,成交额4.05亿元。公司公告汇总关于第六届董事会第二十二次(临时)会议决议公告上海莱士第六届董事会第二十二次(临时)会议于2026年9月23日召开,审议通过《关于收购勃林格殷格翰生物药业(中国)有限公司100%股权暨签署〈收购和出售协议〉及其附属协议的议案》,表决结果为11票同意、0票反对、0票弃权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0196","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670063304","title":"上海莱士:9月24日公司首次回购股份10880400股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670063304","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670063304?lang=zh_cn&edition=full","pubTime":"2026-09-27 20:40","pubTimestamp":1790512800,"startTime":"0","endTime":"0","summary":"证券日报网讯9月27日,上海莱士发布公告称,2026年9月24日,公司首次通过回购专用证券账户以集中竞价方式回购公司股份,回购公司股份数量为10,880,400股,占公司总股本的0.165%,首次回购股份的最高成交价为5.09元/股,最低成交价为4.93元/股,成交总金额为54,534,487.10元(不含交易佣金等交易费用)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-27/doc-inithqpv9321483.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-27/doc-inithqpv9321483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK0188","002252","BK0028","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669742463","title":"全球首创APC机制挺进III期 上海莱士SR604商业化前景如何?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669742463","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669742463?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:40","pubTimestamp":1790239200,"startTime":"0","endTime":"0","summary":"作为全球首个通过抑制APC实现凝血再平衡的血友病治疗药物,SR604属于First-in-class创新品种,结合临床成功率分级标准,Ⅲ期FIC类药物临床成功率取0.40。折现系数方面,上海莱士作为国内成熟的大型血液制品企业,整体经营风险较低,但SR604为First-in-class创新药,当前处于Ⅲ期临床阶段,开发风险高于已成熟的仿制药与生物类似药管线,对应折现率取13%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-24/doc-inisxnuv5181611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","BK0196","002252","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669543870","title":"股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669543870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669543870?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:50","pubTimestamp":1790185827,"startTime":"0","endTime":"0","summary":"公司公告汇总关于第六届董事会第二十二次(临时)会议决议公告上海莱士第六届董事会第二十二次(临时)会议于2026年9月23日召开,审议通过《关于收购勃林格殷格翰生物药业(中国)有限公司100%股权暨签署〈收购和出售协议〉及其附属协议的议案》,表决结果为11票同意、0票反对、0票弃权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002252","BK0188","BK0239","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669102809","title":"上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2669102809","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669102809?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:43","pubTimestamp":1790156639,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海莱士 发布公告,公司拟以现金方式收购勃林格殷格翰(中国)投资有限公司持有的勃林格殷格翰生物药业(中国)有限公司100%股权,预计收购价格不超过2000万元。交易完成后,标的公司将成为公司全资子公司。标的公司建有生物制药合同生产基地,具备6000L规模商业化生产能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002252","BK0239","BK0028","BK0188","BK0196","BK0046","159839"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793545364953,"stockEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.1109},{"period":"3month","weight":-0.0869},{"period":"6month","weight":-0.1431},{"period":"1year","weight":-0.2883},{"period":"ytd","weight":-0.2468}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118982人(较上一季度减少0.84%)","perCapita":"55371股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}